Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
Earlier this month, GSK's (NYSE: GSK) older-adult vaccine candidate for respiratory syncytial virus (RSV) moved one step closer to approval. The U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee voted unanimously (12 to 0) in favor of the vaccine's efficacy and 10 to 2 in favor of its safety. With a decision expected from the FDA by May, the vaccine candidate could launch in time for the next RSV season.